Although these drugs have not been examined in-depth as cancer treatments, their ability to modulate nuclear localization prompted researchers to investigate the effects of combining XPO1 inhibitors with choline salicylate (CH), a drug commonly used to treat rheumatoid arthritis [41]. The gene discussed is XPO1; the disease is cancer.